Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 남은미 | * |
dc.date.accessioned | 2018-12-14T16:30:57Z | - |
dc.date.available | 2018-12-14T16:30:57Z | - |
dc.date.issued | 2018 | * |
dc.identifier.issn | 2523-3548 | * |
dc.identifier.other | OAK-22581 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/247759 | - |
dc.description.abstract | BACKGROUND: Combination therapy with oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) chemotherapy drastically improves survival of advanced pancreatic cancer patients. However, the efficacy of FOLFIRINOX as a second-line treatment after gemcitabine failure has not been tested prospectively. We investigated the feasibility and safety of attenuated FOLFIRINOX in patients with gemcitabine-refractory advanced pancreatic cancer.METHODS: A multicenter phase II prospective open-label, single-arm study was conducted at 14 hospitals. Patients with histologically proven invasive ductal pancreatic adenocarcinoma, a measurable or evaluable lesion, Eastern Cooperative Oncology Group performance status 0 or 1, adequate organ function, and aged 19 years or older were eligible. Attenuated FOLFIRINOX consisted of oxaliplatin 65 mg/m2, irinotecan 135 mg/m2, and leucovorin 400 mg/m2 injected intravenously on day 1 and 5-fluorouracil 2000 mg/m2 continuously infused intravenously over 46 h on days 1-2, repeated every 2 weeks. The primary endpoint was progression-free survival from the initiation of FOLFIRINOX. Secondary endpoints were the objective response rate, disease control rate, overall survival, safety, and tolerability. We estimated overall survival and progression-free survival using the Kaplan-Meier methods.RESULTS: We enrolled 39 patients from 14 institutions. The objective response rate was 10.3%, while the disease control rate was 64.1%. The 6-month and 1-year overall survival rates were 59.0% and 15.4%, respectively. Median progression-free survival and overall survival were 3.8 months (95% confidence interval [CI] 1.5-6.0 months) and 8.5 months (95% CI 5.6-11.4 months), respectively. Grade 3 or 4 adverse events were neutropenia (41.0%), nausea (10.3%), anorexia (10.3%), anemia (7.7%), mucositis (7.7%), pneumonia/pleural effusion (5.1%), and fatigue (5.1%). One treatment-related death attributable to septic shock occurred.CONCLUSION: Attenuated FOLFIRINOX may be promising as a second-line therapy for gemcitabine-refractory pancreatic cancer. | * |
dc.language | English | * |
dc.publisher | NLM (Medline) | * |
dc.subject | Attenuated FOLFIRINOX | * |
dc.subject | Gemcitabine | * |
dc.subject | Pancreatic cancer | * |
dc.subject | Second-line | * |
dc.title | Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study | * |
dc.type | Article | * |
dc.relation.issue | 1 | * |
dc.relation.volume | 38 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 32 | * |
dc.relation.journaltitle | Cancer communications (London, England) | * |
dc.identifier.doi | 10.1186/s40880-018-0304-1 | * |
dc.identifier.wosid | WOS:000434487500001 | * |
dc.identifier.scopusid | 2-s2.0-85055638209 | * |
dc.author.google | Kim J.H. | * |
dc.author.google | Lee S.-C. | * |
dc.author.google | Oh S.Y. | * |
dc.author.google | Song S.-Y. | * |
dc.author.google | Lee N. | * |
dc.author.google | Nam E.M. | * |
dc.author.google | Lee S. | * |
dc.author.google | Hwang I.G. | * |
dc.author.google | Lee H.R. | * |
dc.author.google | Lee K.T. | * |
dc.author.google | Bae S.-B. | * |
dc.author.google | Kim H.J. | * |
dc.author.google | Jang J.S. | * |
dc.author.google | Lim D.H. | * |
dc.author.google | Lee H.W. | * |
dc.author.google | Kang S.Y. | * |
dc.author.google | Kang J.H. | * |
dc.contributor.scopusid | 남은미(7005824288;57226666155) | * |
dc.date.modifydate | 20240301081003 | * |